Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Reptile8488 Deals and Financings Shanghai Mabwell Biosciences (SHA: 688062) out-licensed global rights (ex-China) for a rare disease drug to Disc Medicine (IRON) of Cambridge, MA in a $412.5 million agreement (see story). The candidate, 9MW3011, […]
